Design and biological evaluation of 99mTc-N2S2-Tat(49-57)-c(RGDyK): A hybrid radiopharmaceutical for tumors expressing α(v)β(3) integrins

Nuclear Medicine and Biology

Volumn 40, Issue 4, 2013, Pages 481-487

  Ocampo García, Blanca E ^a   Santos Cuevas, Clara L ^a   De León Rodríguez, Luis M ^b   García Becerra, Rocío ^c   Ordaz Rosado, David ^c   Luna Guitiérrez, Myrna A ^a,d   Jiménez Mancilla, Nallely P ^a,d   Romero Piña, Mario E ^e   Ferro Flores, Guillermina ^a  

^a INSTITUTO NACIONAL DE INVESTIGACIONES NUCLEARES   (Mexico)

^b UNIVERSITY OF GUANAJUATO   (Mexico)

^c INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

^d Esquina Jesús Carranza   (Mexico)

^e INSTITUTO NACIONAL DE CANCEROLOGÍA   (Mexico)

Author keywords

99mTc Tat RGD; Hybrid radiopharmaceutical; Radiolabeled RGD; Tat RGD

Indexed keywords

ARGINYLGLYCYLASPARTIC ACID; ARGINYLGLYCYLASPARTIC ACID TC 99M; CELL PENETRATING PEPTIDE; CYCLIC ARGINYLGLYCYLASPARTYLPHENYLALANYLLYSINE; ETHYLENEDIAMINE N,N' DIACETIC ACID 6 HYDRAZINONICOTINAMIDE DIMER [CYCLIC[ARGINYLGLYCYLASPARTYLPHENYLALANYLLYSINE]] TC 99M; LYSINE; MALEIMIDOPROPIONYL GROUP; N2S2 TRANSACTIVATOR PROTEIN (49-57) CYCLIC (ARGINYLGLYCYLASPARTYLTYROSYLLYSINE) TC 99M; RADIOPHARMACEUTICAL AGENT; SULFIDE; TRACER; TRANSACTIVATOR PROTEIN; TRANSACTIVATOR PROTEIN ARGINYLGLYCYLASPARTIC ACID TC 99M; UNCLASSIFIED DRUG; VITRONECTIN RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING ASSAY; BINDING COMPETITION; CANCER CELL; CONTROLLED STUDY; DIAGNOSTIC IMAGING; DRUG CONJUGATION; DRUG DESIGN; DRUG DISTRIBUTION; DRUG PROTEIN BINDING; DRUG PURITY; DRUG SCREENING; DRUG STABILITY; DRUG TUMOR LEVEL; DRUG UPTAKE; GEL PERMEATION CHROMATOGRAPHY; GLIOBLASTOMA; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IC 50; IN VITRO STUDY; IN VIVO STUDY; INTERNALIZATION; MALE; MICRO-COMPUTED TOMOGRAPHY; MOUSE; NEOPLASM; NONHUMAN; NUDE MOUSE; PROTEIN BINDING; PROTEIN EXPRESSION; SERUM; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TUMOR CELL; TUMOR VASCULARIZATION;

ANIMALS; BIOLOGICAL TRANSPORT; CELL LINE, TUMOR; DRUG DESIGN; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOMA; HUMANS; INTEGRIN ALPHAVBETA3; MALE; MICE; MULTIMODAL IMAGING; OLIGOPEPTIDES; ORGANOTECHNETIUM COMPOUNDS; PEPTIDE FRAGMENTS; RADIOPHARMACEUTICALS; TAT GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS;

EID: 84876714671     PISSN: 09698051     EISSN: 18729614     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2013.01.003     Document Type: Article

References (23)

1. Torchilin V.P. Tat peptide-mediated intracellular delivery of pharmaceutical nanocarriers. Adv Drug Deliv Rev 2008, 60:548-558.
2. Gump J.M., Dowdy S.F. TAT transduction: the molecular mechanism and therapeutic prospects. Trends Mol Med 2007, 13:443-448.
3. 2-Tat(49-57)-bombesin: a target-specific hybrid radiopharmaceutical. Int J Pharm 2009, 375:75-83.
4. Mishra A., Lai G.H., Schmidt N.W., Sun V.Z., Rodriguez A.R., Tong R., et al. Translocation of HIV TAT peptide and analogues induced by multiplexed membrane and cytoskeletal interactions. Proc Natl Acad Sci USA 2011, 108:16883-16888.
5. Buchegger F., Perillo-Adamer F., Dupertuis Y.M., Bischof A. Auger radiation targeted into DNA: a therapy perspective. Eur J Nucl Med Mol Imaging 2006, 33:1352-1363.
6. Howell R. Radiation spectra for Auger-electron emitting radionuclides: report 2 of AAPM Nuclear Medicine Task Group No. 6. Med Phys 1992, 19:1371-1383.
7. Liu S. Radiolabeled multimeric cyclic RGD peptides as integrin alphavbeta3 targeted radiotracers for tumor imaging. Mol Pharm 2006, 3:472-487.
8. 18F-AH111585 in breast cancer patients. J Nucl Med 2008, 49:879-886.
9. Haubner R., Decristoforo C. Radiolabeled RGD peptides and peptidomimetics for tumor targeting. Front Biosciences 2009, 14:872-886.
10. Mitrasinovic P.M. Advances in α(ν)β(3) integrin-targeting cancer therapy and imaging with radiolabeled RGD peptides. Current Radiopharm 2009, 2:214-219.
11. 99mTc-labeled gold nanoparticles conjugated to c[RGDfK(C)] for molecular imaging of tumor α(v)β(3) expression. Bioconjugate Chem 2011, 22:913-922.
12. 177Lu-labeled monomeric, dimeric and multimeric RGD peptides for the therapy of tumors expressing αvβ3 integrins. J Labelled Comp Radiopharm 2012, 50:140-148.
13. 2-Tat(49-57)-bombesin internalized in nuclei of prostate and breast cancer cells: kinetics, dosimetry and effect on cellular proliferation. Nucl Med Comm 2011, 32:303-313.
14. Bandoli G., Dolmella A., Porchia M., Refosco F., Tisato F. Structural overview of technetium compounds (1993-1999). Coord Chem Rev 2001, 214:43-90.
15. 2) technetium-99m complexes: synthesis and biological evaluation as potential renal radiopharmaceuticals. J Med Chem 1993, 36:1032-1040.
16. 111In-octreotide. J Nucl Med 2000, 41:1114-1119.
17. 3]-bombesin for imaging of GRP receptor-positive tumours. Nucl Med Comm 2006, 27:371-376.
18. Miranda-Olvera A.D., Ferro-Flores G., Pedraza-Lopez M., Murphy C.A., De Leon-Rodriguez L.M. Synthesis of oxytocin HYNIC derivatives as potential diagnostic agents for breast cancer. Bioconjugate Chem 2007, 18:1560-1567.
19. 99TcO] apcitide: a technetium labeled peptide. Inorg Chem 2004, 43:2867-2875.
20. Lundqvist H., Stenerlöw B., Gedda L. The Auger effect in molecular targeting therapy. Targeted radionuclide tumor therapy 2008, 195-214. Springer, NewYork. T. Stigbrand, J. Carlsson, G.P. Adams (Eds.).
21. Schally A.V., Nagy A. Cancer chemotherapy based on targeting of cytotoxic peptide conjugates to their receptors on tumors. Eur J Endocrinol 1999, 141:1-14.
22. Buchholz S., Keller G., Schally A.V., Halmos G., Hohla F., Heinrich E., et al. Therapy of ovarian cancers with targeted cytotoxic analogs of bombesin, somatostatin, and luteinizing hormone-releasing hormone and their combinations. Proc Natl Acad Sci USA 2006, 103:10403-10407.
23. Ziegler C.G., Brown J.W., Schally A.V., Erler A., Gebauer L., Treszl A., et al. Expression of neuropeptide hormone receptors in human adrenal tumors and cell lines: antiproliferative effects of peptide analogues. Proc Natl Acad Sci USA 2009, 106:15879-15884.